187 related articles for article (PubMed ID: 21301929)
1. Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients.
Fujiwara Y; Kiyota N; Chayahara N; Suzuki A; Umeyama Y; Mukohara T; Minami H
Invest New Drugs; 2012 Jun; 30(3):1055-64. PubMed ID: 21301929
[TBL] [Abstract][Full Text] [Related]
2. Effect of axitinib (AG-013736) on fatigue, thyroid-stimulating hormone, and biomarkers: a phase I study in Japanese patients.
Mukohara T; Nakajima H; Mukai H; Nagai S; Itoh K; Umeyama Y; Hashimoto J; Minami H
Cancer Sci; 2010 Apr; 101(4):963-8. PubMed ID: 20180805
[TBL] [Abstract][Full Text] [Related]
3. Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma.
Fruehauf J; Lutzky J; McDermott D; Brown CK; Meric JB; Rosbrook B; Shalinsky DR; Liau KF; Niethammer AG; Kim S; Rixe O
Clin Cancer Res; 2011 Dec; 17(23):7462-9. PubMed ID: 21976544
[TBL] [Abstract][Full Text] [Related]
4. Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma.
Tomita Y; Uemura H; Fujimoto H; Kanayama HO; Shinohara N; Nakazawa H; Imai K; Umeyama Y; Ozono S; Naito S; Akaza H;
Eur J Cancer; 2011 Nov; 47(17):2592-602. PubMed ID: 21889330
[TBL] [Abstract][Full Text] [Related]
5. The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Giles FJ; Bellamy WT; Estrov Z; O'Brien SM; Verstovsek S; Ravandi F; Beran M; Bycott P; Pithavala Y; Steinfeldt H; Reich SD; List AF; Yee KW
Leuk Res; 2006 Jul; 30(7):801-11. PubMed ID: 16332390
[TBL] [Abstract][Full Text] [Related]
6. Overall survival and final efficacy and safety results from a Japanese phase II study of axitinib in cytokine-refractory metastatic renal cell carcinoma.
Eto M; Uemura H; Tomita Y; Kanayama H; Shinohara N; Kamei Y; Fujii Y; Umeyama Y; Ozono S; Naito S; Akaza H;
Cancer Sci; 2014 Dec; 105(12):1576-83. PubMed ID: 25283266
[TBL] [Abstract][Full Text] [Related]
7. Axitinib for the management of metastatic renal cell carcinoma.
Escudier B; Gore M
Drugs R D; 2011; 11(2):113-26. PubMed ID: 21679004
[TBL] [Abstract][Full Text] [Related]
8. A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors.
Sharma S; Abhyankar V; Burgess RE; Infante J; Trowbridge RC; Tarazi J; Kim S; Tortorici M; Chen Y; Robles RL
Ann Oncol; 2010 Feb; 21(2):297-304. PubMed ID: 19940012
[TBL] [Abstract][Full Text] [Related]
9. The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma.
Voss MH; Bhatt RS; Plimack ER; Rini BI; Alter RS; Beck JT; Wilson D; Zhang X; Mutyaba M; Glasser C; Attie KM; Sherman ML; Pandya SS; Atkins MB
Clin Cancer Res; 2017 Jul; 23(14):3557-3565. PubMed ID: 28031424
[No Abstract] [Full Text] [Related]
10. Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers.
Pithavala YK; Tong W; Mount J; Rahavendran SV; Garrett M; Hee B; Selaru P; Sarapa N; Klamerus KJ
Invest New Drugs; 2012 Feb; 30(1):273-81. PubMed ID: 20740300
[TBL] [Abstract][Full Text] [Related]
11. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
Eskens FA; Steeghs N; Verweij J; Bloem JL; Christensen O; van Doorn L; Ouwerkerk J; de Jonge MJ; Nortier JW; Kraetzschmar J; Rajagopalan P; Gelderblom H
J Clin Oncol; 2009 Sep; 27(25):4169-76. PubMed ID: 19636022
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial.
Ueda T; Uemura H; Tomita Y; Tsukamoto T; Kanayama H; Shinohara N; Tarazi J; Chen C; Kim S; Ozono S; Naito S; Akaza H
Jpn J Clin Oncol; 2013 Jun; 43(6):616-28. PubMed ID: 23630366
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of axitinib (AG-013736) in combination with gemcitabine in patients with advanced pancreatic cancer.
Spano JP; Moore MJ; Pithavala YK; Ricart AD; Kim S; Rixe O
Invest New Drugs; 2012 Aug; 30(4):1531-9. PubMed ID: 21670972
[TBL] [Abstract][Full Text] [Related]
14. Phase Ib study of CP-868,596, a PDGFR inhibitor, combined with docetaxel with or without axitinib, a VEGFR inhibitor.
Michael M; Vlahovic G; Khamly K; Pierce KJ; Guo F; Olszanski AJ
Br J Cancer; 2010 Nov; 103(10):1554-61. PubMed ID: 20959830
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours.
Martin LP; Kozloff MF; Herbst RS; Samuel TA; Kim S; Rosbrook B; Tortorici M; Chen Y; Tarazi J; Olszanski AJ; Rado T; Starr A; Cohen RB
Br J Cancer; 2012 Oct; 107(8):1268-76. PubMed ID: 22996612
[TBL] [Abstract][Full Text] [Related]
16. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study.
Cohen EE; Rosen LS; Vokes EE; Kies MS; Forastiere AA; Worden FP; Kane MA; Sherman E; Kim S; Bycott P; Tortorici M; Shalinsky DR; Liau KF; Cohen RB
J Clin Oncol; 2008 Oct; 26(29):4708-13. PubMed ID: 18541897
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors.
Chiorean EG; Hurwitz HI; Cohen RB; Schwartz JD; Dalal RP; Fox FE; Gao L; Sweeney CJ
Ann Oncol; 2015 Jun; 26(6):1230-1237. PubMed ID: 25787923
[TBL] [Abstract][Full Text] [Related]
18. A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma.
McNamara MG; Le LW; Horgan AM; Aspinall A; Burak KW; Dhani N; Chen E; Sinaei M; Lo G; Kim TK; Rogalla P; Bathe OF; Knox JJ
Cancer; 2015 May; 121(10):1620-7. PubMed ID: 25565269
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of axitinib and everolimus in metastatic solid tumours and extension to metastatic renal cell carcinoma: Results of EVAX study.
Ravaud A; Gomez-Roca C; Picat MQ; Digue L; Chevreau C; Gimbert A; Chauzit E; Sitta R; Cornelis F; Asselineau J; Aziza R; Daste A; Quemener C; Baud J; Bikfalvi A; Pedenon-Périchout D; Doussau A; Molimard M; Delord JP
Eur J Cancer; 2017 Nov; 85():39-48. PubMed ID: 28886476
[TBL] [Abstract][Full Text] [Related]
20. Concise drug review: pazopanib and axitinib.
van Geel RM; Beijnen JH; Schellens JH
Oncologist; 2012; 17(8):1081-9. PubMed ID: 22733795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
